What are the biomarkers for glaucoma?

Predictive Diagnostics and Personalized Treatment: Dream or Reality

Volumn , Issue , 2009, Pages 376-396

  Golubnitschaja, Olga ^a   Yeghiazaryan, Kristina ^a   Orgül, Selim ^b   Flammer, Josef ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892295625     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (66)

1. Golubnitschaja-Labudova O, Liu R, Decker C, Zhu P, Haefliger IO, Flammer J (2000) Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr. Eye Res., 21, 867-876.
2. de la Monte SM, Xu YY, Hutchins GM, Wands JR (1996) Developmental patterns of neuronal thread protein gene expression in Down syndrome. J. Neurol. Sci., 135, 118-125.
3. Tatton W, Chen D, Chalmers-Redman R, Wheeler L, Nixon R, Tatton N (2003) Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv. Ophthalmol., 48, S25-S37.
4. Quigley HA (1996) Number of people with glaucoma worldwide. Br. J. Ophthalmol., 80, 389-393.
5. Flammer J (2003) Glaucoma. A Guide for Patients. An Introduction for Care-Providers. A Quick Reference. Hogrefe and Huber Publishers.
6. Gugleta K, Orgül S, Flammer J (1999) Asymmetry in intraocular pressure and retinal nerve fiber layer thickness in normal-tension glaucoma. Ophthalmologica, 213, 219-223.
7. Hayreh SS, Podhajsky P, Zimmerman MB (1999) Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica, 213, 76-96.
8. Reddy AB, Panicker SG, Mandal AK, Hasnain SE, Balasubramanian D (2003) Identification of R368H as a predominant CYP1B1 allele causing primary congenital glaucoma in Indian patients. Invest. Ophthalmol. Vis. Sci., 44, 4200-4203.
9. Kanagavalli J, Krishnadas SR, Pandaranayaka E, Krishnaswamy S, Sundaresan P (2003) Evaluation and understanding of myocilin mutations in Indian primary open angle glaucoma patients. Mol. Vis., 14, 606-614.
10. Gong G, Kosoko-Lasaki O, Haynatzki GR, Wilson MR (2004) Genetic dissection of myocilin glaucoma. Hum. Mol. Genet., 13, R91-R102.
11. Mardin CY, Velten I, Ozbey S, Rautenstrauss B, Michels-Rautenstrauss K (1999) A GLC1A gene Gln368Stop mutation in a patient with normal-tension open-angle glaucoma. J. Glaucoma, 8, 154-156.
12. Colomb E, Kaplan J, Garchon HJ (2003) Novel cytochrome P450 1B1 (CYP1B1) mutations in patients with primary congenital glaucoma in France. Hum. Mutat., 22, 496.
13. Howell N (2003) LHON and other optic nerve atrophies: the mitochondrial connection. Dev. Ophthalmol., 37, 94-108.
14. Leung YF, Fan BJ, Lam DS, Lee WS, Tam PO, Chua JK, Tham CC, Lai JS, Fan DS, Pang CP (2003) Different optineurin mutation pattern in primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci., 44, 3880-3884.
15. Mackey DA, Craig JE (2003) Predictive DNA testing for glaucoma: reality in 2003. Ophthalmol. Clin. North Am., 16, 639-645.
16. Polansky JR (2003) Current perspectives on the TIGR/MYOC gene (Myocilin) and glaucoma. Ophthalmol. Clin. North Am., 16, 515-527, v-vi.
17. Panicker SG, Mandal AK, Reddy AB, Gothwal VK, Hasnain SE (2004) Correlations of genotype with phenotype in Indian patients with primary congenital glaucoma. Invest Ophthalmol. Vis. Sci., 45, 1149-1156.
18. Herndon LW, Challa P, Allingham RR (2003) Glaucoma in Ghana, West Africa: clinical features and the role of mutations in Myocilin. Ophthalmol. Clin. North Am., 16, 631-637.
19. Bruttini M, Longo I, Frezzotti P, Ciappetta R, Randazzo A, Orzalesi N, Fumagalli E, Caporossi A, Frezzotti R, Renieri A (2003) Mutations in the myocilin gene in families with primary open-angle glaucoma and juvenile open-angle glaucoma. Arch. Ophthalmol., 121, 1034-1038.
20. Kanagavalli J, Krishnadas SR, Pandaranayaka E, Krishnaswamy S, Sundaresan P (2003) Evaluation and understanding of myocilin mutations in Indian primary open angle glaucoma patients. Mol. Vis., 14, 606-614.
21. Melki R, Idhajji A, Driouiche S, Hassani M, Boukabboucha A, Akhayat O, Garchon H, Belmouden A (2003) Mutational analysis of the Myocilin gene in patients with primary open-angle glaucoma in Morocco. Ophthalmic. Genet., 24, 153-160.
22. Wiggs JL, Auguste J, Allingham RR, Flor JD, Pericak-Vance MA, Rogers K, LaRocque KR, Graham FL, Broomer B, Del Bono E, Haines JL, Hauser M (2003) Lack of association of mutations in optineurin with disease in patients with adult-onset primary open-angle glaucoma. Arch. Ophthalmol., 121, 1181-1183.
23. Sripriya S, Uthra S, Sangeetha R, George RJ, Hemamalini A, Paul PG, Amali J, Vijaya L, Kumaramanickavel G (2004) Low frequency of myocilin mutations in Indian primary open-angle glaucoma patients. Clin. Genet., 65, 333-337.
24. Flammer J, Pache M, Resink T (2001) Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog. Retin. Eye Res., 20, 319-349.
25. Finsterer J (2004) Mitochondriopathies. Eur. J. Neurol., 11, 163-186.
26. Flammer J, Guthauser U, Mahler M (1987) Do ocular vasospasms help cause low-tension glaucoma? Doc. Ophthalmol. Proc. Ser., 49, 397-399.
27. Guthauser U, Flammer J, Mahler F (1988) The relationship between digital and ocular vasospasm. Graefes Arch. Clin. Exp. Ophthalmol., 226, 224-226.
28. Flammer J, Orgül S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefánsson E (2002) The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res., 21, 359-393.
29. Yang J, Patil RV, Yu H, Gordon M, Wax MB (2001) T cell subsets and sIL-2R/IL-2 levels in patients with glaucoma. Am. J. Ophthalmol., 131, 421-426.
30. Grus FH, Joachim SC, Bruns K, Lackner KJ, Pfeiffer N, Wax MB (2006) Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest. Ophthalmol. Vis. Sci., 47, 968-976.
31. Tomarev SI, Wistow G, Raymond V, Dubois S, Malyukova I (2003) Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Invest. Ophthalmol. Vis. Sci., 44, 2588-2596.
32. Flammer J, Mozaffarieh M (2007) What is the present pathogenetic concept of glaucoma? Surv. Ophthalmol., 52(Suppl 2), S162-S173.
33. Moenkemann H, Flammer J, Wunderlich K, Breipohl W, Schild HH, Golubnitschaja O (2005) Increased DNA breaks and up-regulation of both G(1) and G(2) checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in circulating leukocytes of glaucoma patients and vasospastic individuals. Amino Acids, 28, 199-205.
34. Golubnitschaja O, Moenkemann H, Kim K, Mozaffari MS (2003) DNA damage and expression of checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in taurine-deficient cardiomyocytes. Biochem. Pharmacol., 66, 511-517.
35. Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L (2005) Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol. Aging, 26, 587-595.
36. Golubnitschaja O, Yeghiazaryan K, Wunderlich K, Schild HH, Orgul S, Golubnitschaja O (2007) Disease proteomics reveals altered basic gene expression regulation in leukocytes of glaucoma patients. Proteomics Clin. Appl., 1, 1316-1323.
37. Tezel G, Yang X, Cai J (2005) Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest. Ophthalmol. Vis. Sci., 46, 3177-3187.
38. Ahmed F, Brown KM, Stephan DA, Morrison JC, Johnson EC, Tomarev SI (2004) Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure. Invest. Ophthalmol. Vis. Sci., 45, 1247-1258.
39. Wunderlich K, Golubnitschaja O, Pache M, Eberle AN, Flammer J (2002) Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study. Mol. Vis., 8, 431-435.
40. Golubnitschaja O, Fountoulakis M (2007) Gene hunting by substractive hybridisation in Down syndrome. Correlation with proteomics analysis, in: Handbook of Neurochemistry and Molecular Neurobiology. Genomics, Proteomics and the Nervous System. Springer Verlag, Berlin.
41. Golubnitschaja O, Wunderlich K, Decker C, Mönkemann H, Schild HH, Flammer J (2002) Molecular imaging of perfusion disturbances in glaucoma. Amino Acids, 23, 293-299.
42. Grieshaber MC, Flammer J (2007) Does the blood-brain-barrier play a role in Glaucoma? Surv. Ophthalmol., 52 (Suppl 2), S144-S154.
43. Golubnitschaja O, Yeghiazaryan K, Liu R, Mönkemann H, Leppert D, Schild H, Haefliger IO, Flammer J (2004) Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J. Glaucoma, 13, 66-72.
44. Diskin S, Kumar J, Cao Z, Schuman JS, Gilmartin T, Head SR, Panjwani N (2006) Detection of differentially expressed glycogenes in trabecular meshwork of eyes with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci., 47, 1491-1499.
45. Bhattacharya SK, Rockwood EJ, Smith SD, Bonilha VL, Crabb JS, Kuchtey RW, Robertson NG, Peachey NS, Morton CC, Crabb JW (2005) Proteomics reveal Cochlin deposits associated with glaucomatous trabecular meshwork. J. Biol. Chem., 280, 6080-6084.
46. Fleenor DL, Pang IH, Clark AF (2003) Involvement of AP-1 in interleukin-1alpha-stimulated MMP-3 expression in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci., 44, 3494-3501.
47. Pang IH, Fleenor DL, Hellberg PE, Stropki K, McCartney MD, Clark AF (2003) Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. Invest. Ophthalmol. Vis. Sci., 44, 3502-3510.
48. Mohan R, Rinehart WB, Bargagna-Mohan P, Fini ME (1998) Gelatinase B/lacZ transgenic mice, a model for mapping gelatinase B expression during developmental and injury-related tissue remodeling. J. Biol. Chem., 273, 25903-25914.
49. Esser J, Esser P, Mietz H, Hueber A, Kociok N, Schraermeyer U, Krieglstein GK (2000) Multidrug resistance-associated proteins in glaucoma surgery. Graefes Arch. Clin. Exp. Ophthalmol., 238, 727-732.
50. Yeghiazaryan K, Flammer J, Wunderlich K, Schild HH, Orgul S, Golubnitschaja O (2005) An enhanced expression of ABC 1 transporter in circulating leukocytes as a potential molecular marker for the diagnostics of glaucoma. Amino Acids, 28, 207-211.
51. Joyce CW, Amar MJ, Lambert G, Vaisman BL, Paigen B, Najib-Fruchart J, Hoyt RF Jr, Neufeld ED, Remaley AT, Fredrickson DS, Brewer HB Jr, Santamarina-Fojo S (2002) The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Natl. Acad. Sci. U.S.A., 99, 407-412.
52. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES (2003) Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation, 107, 2944-2948.
53. Pechere-Bertschi A, Sunaric-Megevand G, Haefliger IO, Panarello F, Maillard M, Burnier M (2007) Renal sodium handling in patients with normal pressure glaucoma. Clin. Sci. (Lond), 112, 337-344.
54. Schwartz B, Abrahamson R, Takamoto T, Wysocki A (2000) Association of ocular pressure and optic disc cup volume with red blood cell sodium-potassium ATPase inhibition. Curr. Eye Res., 21, 897-905.
55. Salomon P, Mysiak A, Halawa B (1998) Sodium efflux through lymphocytic cell membranes in patients with acute myocardial infarction. Pol. Arch. Med. Wewn., 100, 543-550.
56. Stark G (2005) Functional consequences of oxidative membrane damage. J. Membr. Biol., 205, 1-16.
57. Silva JE (1995) Thyroid hormone control of thermogenesis and energy balance. Thyroid, 5, 481-492.
58. Valdemarsson S, Ikomi-Kumm J, Monti M (1992) Increased lymphocyte thermogenesis in hyperthyroid patients. Role of Na/K pump function. Evaluation of aerobic/anaerobic metabolism. Acta Endocrinol. (Copenh), 126, 291-295.
59. Bagrov AY, Dmitrieva RI, Fedorova OV, Kazakov GP, Roukoyatkina NI, Shpen VM (1996) Endogenous marinobufagenin-like immunoreactive substance. A possible endogenous Na, K-ATPase inhibitor with vasoconstrictor activity. Am. J. Hypertens., 9, 982-990.
60. van den Bergh WM, Dijkhuizen RM, Rinkel GJ (2004) Potentials of magnesium treatment in subarachnoid haemorrhage. Magnes. Res., 17, 301-313.
61. Kanagavalli J, Krishnadas SR, Pandaranayaka E, Krishnaswamy S, Sundaresan P (2003) Evaluation and understanding of myocilin mutations in Indian primary open angle glaucoma patients. Mol. Vis., 9, 606-614.
62. Kotikoski H, Moilanen E, Vapaatalo H, Aine E (2002) Biochemical markers of the L-arginine-nitric oxide pathway in the aqueous humour in glaucoma patients. Acta Ophthalmol. Scand, 80, 191-195.
63. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P (1994) Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology, 101, 454-460.
64. Souchier M, Buron N, Lafontaine PO, Bron AM, Baudouin C, Creuzot-Garcher C (2006) Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery? Br. J. Ophthalmol., 90, 1366-1369.
65. Golubnitschaja O, Flammer J International Patent No. IB02/00648.
66. Golubnitschaja O, Flammer J (2007) What are the biomarkers for glaucoma? Surv. Ophthalmol., 52, S155-S161.